iCAD to Present at Rodman & Renshaw 11th Annual Global Investment Conference

Webcast Scheduled for September 9, 2009 at 2:50 p.m. Eastern Time

• Press Release
• Source: iCAD, Inc.
• On 9:00 am EDT, Wednesday September 2, 2009

NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ: ICAD - News), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will be presenting a corporate update at the Rodman & Renshaw 11^th Annual Global Investment Conference on September 9, 2009 at 2:50 p.m. (Eastern time) being held at the New York Palace Hotel in New York City.

Related Quotes

Symbol	Price	Change
ICAD	1.54	0.00

{"s" : "icad","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Management will also be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Growth Conference. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your Rodman & Renshaw representative.

The presentation will be webcast live and archived for replay on the “Investors” section of the company’s website at www.icadmed.com and at http://www.wsw.com/webcast/rrshq15/icad.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD
Darlene Deptula-Hicks, 603-882-5200 x7944
EVP and CFO
ddeptula@icadmed.com
or
For iCAD Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD Public Relations
MS&L
Liza Heapes, 617-369-8787
liza.heapes@mslworldwide.com